AptarGroup (ATR)
NYSEMaterialsMedical - Instruments & SuppliesSnapshot 2026-09-04
$127.41-0.70%
Close 2026-09-04 · 1-day change
NYSEMaterialsMedical - Instruments & SuppliesSnapshot 2026-09-04
QuarterlyIQ Insights · ATR
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 29.7% |
| Our one-year growth estimate | diamond | 4.0% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 25.7 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 25 industry peers
ATR — CEO transition
Dated 2026-09-01
Director — Gael Touya: The filing discloses the appointment of Gael Touya as a director, which is a routine board expansion and appointment event, distinct from the previously disclosed CEO succession.
Why it matters: Steady revenue growth shows management's strategy works and there is market demand. This affects investor confidence.
Supportive ifReported sales growth remains above 6% across all segments in Q3.
Worry ifIf sales growth drops below 6%, it may show market weakness.
Why it matters: Growth in Beauty shows strong demand from consumers and a good market position.
Supportive ifBeauty segment sales growth remains above 10% in Q2 2026.
Worry ifBeauty segment sales growth is below 5%. This signals possible market weakness.
Why it matters: Supply chain problems may hurt revenue and margins. Watching this helps check stability.
Watch forQ2 results show minimal impact from supply chain issues.
Also watch forQ2 results show a big negative effect from supply chain problems.
Why it matters: News on capital spending shows how Aptar is investing for growth and controlling costs.
Watch forManagement says they will spend between $260 million and $280 million.
Also watch forManagement cuts capital spending to less than $260 million.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$77 on $10,000 · ±0.8% | How much price usually moves either way. |
| Bad day | $247 loss on $10,000 · 2.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,318 loss on $10,000 · 23.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The new CEO's plans could reshape Aptar's direction and impact growth. Early signals are important.
Supportive ifAptar shares new plans from the new CEO that match growth goals.
Worry ifNo clear initiatives or direction are announced by the new CEO.
Why it matters: Supply chain issues could affect production and sales. Monitoring this helps gauge operational risks.
Watch forAptar reports no big supply chain problems in Q2.
Also watch forAptar says there are major supply chain problems affecting Q2 results.
Why it matters: More share repurchases show confidence in the company. This can help share prices.
Supportive ifAptar plans to repurchase over $100 million in shares next quarter.
Worry ifNo major share repurchase activity happens in the next quarter.
Why it matters: This range indicates management's confidence in ongoing growth across segments. Meeting or exceeding this range would show strong performance.
Supportive ifQ3 adjusted earnings per share reported at or above $1.53.
Worry ifQ3 adjusted earnings per share reported below $1.45.
Why it matters: A stable margin shows good cost control. It means Aptar can stay profitable while growing.
Supportive ifEBITDA margin was above 20% in Q3.
Worry ifEBITDA margin was below 20% in Q3.
Why it matters: Share buybacks show management trusts the stock. They can also help returns for shareholders.
Supportive ifA new share buyback program over $100 million was announced.
Worry ifNo new share repurchase announcements made after Q3.
Why it matters: Pharma growth is crucial for overall revenue. Strong performance here signals effective demand for key products.
Supportive ifPharma segment sales growth reported above 5% year over year.
Worry ifPharma segment sales growth reported below 0% year over year.